← Latest news 
Torrent wins 38 percent share as semaglutide generics surge across India
Economy
Published on 7 May 2026
A dozen companies raced in after the patent expiry
After Novo Nordisk’s innovator semaglutide patent expired in end-March, over a dozen Indian firms launched generics. In April, these generics sold about ₹44 crore in total, with Torrent emerging as the fastest mover, grabbing around 38% market share. The sprint signals intensifying competition in GLP-1 diabetes and weight-management drugs.
- Novo Nordisk patent expiry in end-March opened the market
- More than a dozen Indian companies launched semaglutide generics
- Generic semaglutide sales reached about ₹44 crore in April
- Torrent captured roughly 38% market share quickly
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times